Berry Genomics (000710.SZ) has forecasted a preliminary loss, with an estimated net loss of 170 million to 250 million yuan for the fiscal year 2024.

Berry Genomics (000710.SZ) issued the performance forecast for 2024, expecting a net loss of RMB 170 million to RMB 250 million attributable to the shareholders of the listed company for the full year. During the reporting period, the competition in the genetic testing market remained intense. Faced with a complex market environment, the company focused on its core business, tightened its operating strategies, concentrated on revitalizing assets, and worked hard to enhance its core competitiveness to strengthen the company's sustainable operating capability. It is expected that the annual operating income will slightly decrease, the comprehensive gross profit margin will slightly increase, and the operating net cash flow indicator will continue to improve.